Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab and Derazantinib in Advanced Intrahepatic Cholangiocarcinoma With FGFR2
NCT05174650Phase 2Active, not recruiting
- Sponsor
- Institut für Klinische Krebsforschung
- Start
- Apr 2022
- Primary completion
- Dec 2025
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of atezolizumab, derazantinib in intrahepatic cholangiocarcinoma (ICC), sponsored by Institut für Klinische Krebsforschung. Started Apr 2022; status: active, not recruiting.
02
Drugs
atezolizumabderazantinib
03
Conditions
intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on NCT05174650.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05174650.